Targeted immunotherapy of cancer with CAR T cells: achievements and challenges Grazyna Lipowska-BhallaDavid E. GilhamDominic G. Rothwell Review 22 April 2012 Pages: 953 - 962
Is an immune reaction required for malignant transformation and cancer growth? Richmond T. PrehnLiisa M. Prehn Perspectives Open access 18 May 2012 Pages: 963 - 966
Harmonization of the intracellular cytokine staining assay Marij J. P. WeltersCécile GouttefangeasSjoerd H. van der Burg Original article Open access 22 May 2012 Pages: 967 - 978
Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes Dongmei LaiFangyuan WangLihe Guo Original article 27 November 2011 Pages: 979 - 989
Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells Tracy R. DanielsRichard K. LeuchterManuel L. Penichet Original Article 30 November 2011 Pages: 991 - 1003
Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy Fernanda V. CastroMariam Al-MuftahPeter L. Stern Original Article 30 November 2011 Pages: 1005 - 1018
An immune-active tumor microenvironment favors clinical response to ipilimumab Rui-Ru JiScott D. ChasalowVafa Shahabi Original article 07 December 2011 Pages: 1019 - 1031
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient An M. T. Van NuffelDaphné BenteynAude Bonehill Original article 10 December 2011 Pages: 1033 - 1043
Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer Kristoffer Watten BrudvikKaren HenjumKjetil Taskén Original article 11 December 2011 Pages: 1045 - 1053
Collective action of hematopoietic cell subsets mediates anti-IL10R1 and CpG tumor immunity Meng-Yun ChouCary D. AustinJeong M. Kim Original article 11 December 2011 Pages: 1055 - 1064
Activation-induced cell death of memory CD8+ T cells from pleural effusion of lung cancer patients is mediated by the type II Fas-induced apoptotic pathway Heriberto Prado-GarciaSusana Romero-GarciaJose Sullivan Lopez-Gonzalez Original Article 13 December 2011 Pages: 1065 - 1080
Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors Hideyuki NakashimaKotaro MiyakeKathryn C. Zoon Original article 13 December 2011 Pages: 1081 - 1092
Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes Christina S. MullinsMichael Linnebacher Original article 21 December 2011 Pages: 1093 - 1100
The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues Jurjen TelStanleyson V. HatoI. Jolanda M. de Vries Original article Open access 23 December 2011 Pages: 1101 - 1111
Exploiting antitumor immunity to overcome relapse and improve remission duration Lei L. ChenXinjian ChenRobert S. Benjamin Original article Open access 24 December 2011 Pages: 1113 - 1124
Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy Katayoun RezvaniAgnes S. M. YongA. John Barrett Original article 24 December 2011 Pages: 1125 - 1136
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer Douglas G. McNeelHeath A. SmithGlenn Liu Original Article 31 December 2011 Pages: 1137 - 1147
Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy Angela J. ZiebarthMildred A. FelderJoseph P. Connor Short Communication 06 May 2012 Pages: 1149 - 1153